urgency removes friction

a biotech founder's team went from finding a mutation to dosing two als patients in seven months. partners waived fees and skipped contracts because a patient was dying.

share x linkedin facebook

a dotted path runs across a sunlit meadow toward a glowing freestanding door, with a small group of people walking together near the start and a bright sun above

friday evening i taped an episode with a founder who designs rna drugs with software. she told me a story about speed that i haven't been able to stop thinking about.

her team went from identifying a disease mutation to dosing two als patients in about seven months. in drug development that's almost unheard of.

i asked her what made it possible. i expected an answer about ai. the first answer was about people.

partners and service providers waived their fees. they skipped the long contracting cycles. they did it because they heard there was a dying patient on the other end. a regulatory path for one-patient treatments helped too. instead of a full battery of animal studies, they needed a single rat study, and once they had approval they dosed the patient the next day.

so the biggest accelerant wasn't technology. it was urgency that everyone in the chain could feel.

that's worth thinking about for any company. most of the delay in your business isn't the work. it's the friction around the work. contracts sitting in legal. approvals waiting on someone's calendar. a partner who'll get to it next month. when everyone believes it matters right now, most of that friction disappears.

you can't fake a dying patient, and you shouldn't try. but you can make the stakes real and visible to your partners. tell them what happens if this ships late. tell them who's waiting. people move faster for a person than for a purchase order.

the technology part of her story is impressive too. she said one well known rna drug took the original team more than six hundred designed molecules and about ten years to find. her software found the same candidate from about twenty. her view is that with the right platform almost any target becomes druggable, because the molecule can turn a gene up, turn it down or fix how it's spliced.

i pushed her for plain english on why twenty candidates is enough. her answer was that each small screen teaches the model something, so the next round of predictions gets better.

and the survival story might be the most useful part for founders. her company went through about five years when venture money wasn't available to them. they stayed alive by selling development services for rare disease and licensing part of their software. she was proud of it, and she should be. lean, creative, revenue first, while waiting for the market to come back.

i hear founders say they can't do anything until the round closes. she built a company through five years without one.

long term, i think ai will shrink the design part of hard science from years to weeks. what's left will be the human chain around it... and the teams that can make that chain move with urgency will win.

if you're trying to fund something hard, here's how i help founders raise.

so where's the friction in your company that would disappear tomorrow if everyone could see who's waiting?

share x linkedin facebook
the newsletter

the machine economy brief

one email when it matters: bitcoin, ai, robotics, and what founders should do about it. unsubscribe anytime.

no spam, no list-selling. your email goes to sunny, nowhere else.

this is the thesis i'm building on.

i write the machine economy brief: bitcoin x ai x robotics, where it's all going, once a week.

join the machine economy brief →